BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 29361410)

  • 1. [Presentation and outcome of breast cancer under 40 years - A French monocentric study].
    Fleurier C; Pilloy J; Chas M; Cirier J; Jourdan ML; Arbion F; Body G; Ouldamer L
    Gynecol Obstet Fertil Senol; 2018 Feb; 46(2):105-111. PubMed ID: 29361410
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Value of Ki67 in Very Young Women with Hormone Receptor-Positive Breast Cancer: Retrospective Analysis of 9,321 Korean Women.
    Kim J; Han W; Jung SY; Park YH; Moon HG; Ahn SK; Lee JW; Kim MK; Kim JJ; Lee ES; You TK; Kang HS; Lee ES; Ro J; Lee JE; Nam SJ; Yim YH; Park IA; Noh DY
    Ann Surg Oncol; 2015 Oct; 22(11):3481-8. PubMed ID: 25652052
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Breast cancer with triple-negative phenotype in the Russian patient population. Clinical and morphologic features].
    Zhukova LG
    Vopr Onkol; 2015; 61(2):189-94. PubMed ID: 26087596
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Impact of pathological complete response to neoadjuvant chemotherapy in invasive breast cancer according to molecular subtype].
    Cirier J; Body G; Jourdan ML; Bedouet L; Fleurier C; Pilloy J; Arbion F; Ouldamer L
    Gynecol Obstet Fertil Senol; 2017 Oct; 45(10):535-544. PubMed ID: 28939364
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential expression of prognostic factors and effect on survival in young (< or =40) breast cancer patients: a case-control study.
    Hartley MC; McKinley BP; Rogers EA; Kalbaugh CA; Messich HS; Blackhurst DW; Lokey JS; Trocha SD
    Am Surg; 2006 Dec; 72(12):1189-94; discussion 1194-5. PubMed ID: 17216817
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Influence of hormonal factors on triple-negative breast cancer prognosis].
    Weymuller V; Caille A; Diguisto C; Chas M; Jourdan ML; Arbion F; Body G; Ouldamer L
    Gynecol Obstet Fertil Senol; 2019 May; 47(5):471-477. PubMed ID: 30872189
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Breast cancer in young women: Pathologic features and molecular phenotype.
    Sabiani L; Houvenaeghel G; Heinemann M; Reyal F; Classe JM; Cohen M; Garbay JR; Giard S; Charitansky H; Chopin N; Rouzier R; Daraï E; Coutant C; Azuar P; Gimbergues P; Villet R; Tunon de Lara C; Lambaudie E
    Breast; 2016 Oct; 29():109-16. PubMed ID: 27479041
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Different prognosis of young breast cancer patients in their 20s and 30s depending on subtype: a nationwide study from the Korean Breast Cancer Society.
    Ryu JM; Yu J; Kim SI; Kim KS; Moon HG; Choi JE; Jeong J; Do Byun K; Nam SJ; Lee JE; Lee SK; Kim SW
    Breast Cancer Res Treat; 2017 Dec; 166(3):833-842. PubMed ID: 28831642
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic impact of triple negative phenotype in conservatively treated breast cancer.
    Barbieri V; Sanpaolo P; Genovesi D
    Breast J; 2011; 17(4):377-82. PubMed ID: 21615820
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Progesterone receptor status and clinical outcome in breast cancer patients with estrogen receptor-positive locoregional recurrence.
    Bogina G; Lunardi G; Coati F; Zamboni G; Gori S; Bortesi L; Marconi M; Cassandrini PA; Turazza M; Cortesi L; DeMatteis E; Ficarra G; Ibrahim T; Serra P; Medri L; Giraudi S; Lambertini M; Carli F; Foglietta J; Sidoni A; Nunzi M; Ficorella C; Diadema MR; Del Mastro L
    Tumori; 2015; 101(4):398-403. PubMed ID: 26045108
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Prognostic value of estrogen receptor, progesterone receptor and human epidermal growth factor receptor-2 in node positive breast cancer patients treated by mastectomy].
    Wang SL; Li YX; Song YW; Wang WH; Jin J; Liu YP; Liu XF; Yu ZH
    Zhonghua Zhong Liu Za Zhi; 2010 Jul; 32(7):520-5. PubMed ID: 21029696
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Distribution and prognosis of molecular breast cancer subtypes defined by immunohistochemical biomarkers in a Spanish population-based study.
    Puig-Vives M; Sánchez MJ; Sánchez-Cantalejo J; Torrella-Ramos A; Martos C; Ardanaz E; Chirlaque MD; Perucha J; Díaz JM; Mateos A; Machón M; Marcos-Gragera R
    Gynecol Oncol; 2013 Sep; 130(3):609-14. PubMed ID: 23747837
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical features and survival analysis of T1mic, a, bN0M0 breast cancer.
    Li J; Liu X; Tong Z
    Jpn J Clin Oncol; 2012 Jun; 42(6):471-6. PubMed ID: 22493058
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer.
    Haffty BG; Yang Q; Reiss M; Kearney T; Higgins SA; Weidhaas J; Harris L; Hait W; Toppmeyer D
    J Clin Oncol; 2006 Dec; 24(36):5652-7. PubMed ID: 17116942
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Breast cancer in very young women.
    Liukkonen S; Leidenius M; Saarto T; Sjöström-Mattson J
    Eur J Surg Oncol; 2011 Dec; 37(12):1030-7. PubMed ID: 21937191
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Estrogen receptor, progesterone receptor, HER-2, and response to postmastectomy radiotherapy in high-risk breast cancer: the Danish Breast Cancer Cooperative Group.
    Kyndi M; Sørensen FB; Knudsen H; Overgaard M; Nielsen HM; Overgaard J;
    J Clin Oncol; 2008 Mar; 26(9):1419-26. PubMed ID: 18285604
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Clinical characteristics and prognosis of triple-negative breast cancer: a report of 305 cases].
    Yuan ZY; Wang SS; Gao Y; Su ZY; Luo WB; Guan ZZ
    Ai Zheng; 2008 Jun; 27(6):561-5. PubMed ID: 18570725
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The variation and clinical significance of hormone receptors and Her-2 status from primary to metastatic lesions in breast cancer patients.
    Zhu YY; Si W; Ji TF; Guo XQ; Hu Y; Yang JL
    Tumour Biol; 2016 Jun; 37(6):7675-84. PubMed ID: 26687919
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clinical characteristics and survival in the operable breast cancer patients with different molecular subtypes].
    Zhang HM; Zhang BN; Xuan LX; Zhao P
    Zhonghua Zhong Liu Za Zhi; 2009 Jun; 31(6):447-51. PubMed ID: 19950556
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Receptor discordance rate and its effects on survival in primary and recurrent breast cancer patients.
    Ilgun S; Sarsenov D; Erdogan Z; Ordu C; Celebi F; Nur Pilanci K; Ozturk A; Selamoglu D; Alco G; Aktepe F; Eralp Y; Tuzlali S; Ozmen V
    J BUON; 2016; 21(6):1425-1432. PubMed ID: 28039703
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.